|
Dogface, you are right. The Street seems to be waiting, as we all are , for news of the diabetes deal. Simultaneously, in a parallel universe, ERGO investors await the same sort of news. ERGO is way out ahead of LGND however. ERGO has already completed Phase III trials for diabetes, has announced positive results, and has filed its NDA. H7Q, UBS, Cowen, et al all predict that a diabetes partner for ERGO is imminent. Who could it be? JNJ? Perhaps. Would it not be pre4ferable to license a drug (Ergoset) which has already demonstrated strong safety and efficacy data in Phase III testing, and for which the NDA has already been filed, than to license an earlier stage drug (Targretin) on which the jury is still out? Even if successful, Targretin will be entering the market at least two or more years after Ergoset has already established its presence. Care to comment Dog, Henry, anyone? |
